HCM Medical
HCM Medical (now LifeNet Health Advanced Xeno-Therapeutics) is a Netherlands-based contract manufacturing organization that uses proprietary supercritical CO2 processing to produce biological and biomaterial-based medical products — including decellularized tissue scaffolds, collagen devices, and Investigational Medicinal Products — for medical device and pharmaceutical companies worldwide.
- Company typePrivate
- Founded2014
- HeadquartersNijmegen, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What HCM Medical does
HCM Medical, founded in 2014 in Nijmegen, Netherlands, by biochemists Henriette Valster and Christian van Munster, operated as a Contract Manufacturing Organization (CMO) specializing in biological and biomaterial-based medical products. The company's core capability centered on supercritical CO2 (scCO2) processing technology — a solvent-free, low-temperature method for decellularization, purification, impregnation, and terminal sterilization of xenograft and allograft tissues. This was combined with freeze drying, collagen extraction and purification from multiple animal sources (bovine, porcine, equine), and aseptic handling in ISO Class 5-7 / GMP Class A/B/C cleanrooms. The technology stack enabled production of decellularized extracellular matrix (dECM) scaffolds, collagen membranes, bone fillers, and Investigational Medicinal Products (IMPs) for clinical studies.
The business model was B2B contract manufacturing, serving international medical device and pharmaceutical companies requiring specialized biologics manufacturing from prototype through commercial scale. Revenue was generated via project-based and recurring manufacturing contracts, with pricing negotiated on a project basis given complexity, volume, and regulatory requirements. Customer segments included medical device companies (primary), pharmaceutical and biotech firms (for GMP-licensed IMP production), and downstream use cases spanning orthopedics, dentistry, wound care, and cardiovascular repair. The company held ISO 13485:2016, GMP for IMPs, WVKL tissue establishment recognition, and NVWA category 3-material manufacturing authorization, collectively forming a significant regulatory barrier.
In August 2025, LifeNet Health acquired HCM Medical to expand its regenerative medicine biologics manufacturing footprint and address growing global demand. The company was rebranded as LifeNet Health Advanced Xeno-Therapeutics in June 2026, integrating the proprietary closed-herd xenograft platform, antibiotic-coated implant technologies, and next-generation scCO2 sterilization methods into the parent organization's global distribution network. As of the most recent data, the Nijmegen facility operated with approximately 28 employees.
HCM Medical firmographics
Firmographics- Name
- HCM Medical
- Legal name
- HCM Medical B.V.
- Website
- http://hcm-medical.com/
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- HCM Medical (now LifeNet Health Advanced Xeno-Therapeutics) is a Netherlands-based contract manufacturing organization that uses proprietary supercritical CO2 processing to produce biological and biomaterial-based medical products — including decellularized tissue scaffolds, collagen devices, and Investigational Medicinal Products — for medical device and pharmaceutical companies worldwide.
- Ownership category
- akta.pro rank
HCM Medical industry classification
Industry- Product category
- Contract Biologics Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industry
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where HCM Medical is headquartered
LocationHeadquarters
- HQ city
- Nijmegen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
HCM Medical business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Organization (CMO) Services: HCM Medical acts as a B2B contract manufacturing partner for medical device and pharmaceutical companies. Services span product development, prototyping, scale-up, and routine manufacturing of biologics, tissue constructs, collagen-based products, and medical implants. Revenue is generated through project-based and recurring manufacturing contracts with international clients. As a GMP-licensed manufacturer, it also produces Investigational Medicinal Products (IMPs) for clinical studies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
HCM Medical product offering
Product offeringCore offering
HCM Medical (now LifeNet Health Advanced Xeno-Therapeutics) is a Contract Manufacturing Organization (CMO) that produces biological and biomaterial-based medical products for medical device and pharmaceutical companies. It transforms human and animal tissues into ISO/GMP-compliant medical implants—including collagen products, decellularized extracellular matrix (dECM) scaffolds, xenografts, and Investigational Medicinal Products (IMPs)—using proprietary supercritical CO2 (scCO2) processing, freeze drying, and aseptic handling in ISO Class 5-7 cleanrooms.
Product overview
HCM Medical (now LifeNet Health Advanced Xeno-Therapeutics) is a Contract Manufacturing Organization (CMO) specializing in biological and biomaterial-based medical products. The company operates as a unified platform combining multiple technologies and services: CMO services for ISO/GMP-compliant production of medical devices and Investigational Medicinal Products (IMPs); Collagen Products including medical collagen membranes, powder, pads, and dECM scaffolds derived from animal and human tissues; and proprietary processing technologies (ScCO2 processing, freeze drying, aseptic handling) that transform raw biomaterials into certified medical implants for wound care, orthopedics, dental, and cardiovascular applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Manufacturing Organization (CMO) Services ISO- and GMP-compliant contract manufacturing services for biological and biomaterial-based medical products, including production in ISO Class cleanrooms from small-scale clinical batches to larger commercial runs. Designed for medical device and pharmaceutical companies.
- Collagen Products Medical collagen products derived from animal sources (equine, bovine, porcine, fish) in various forms including powder, pads, membranes, and 3D structures for wound care, surgical implants, and tissue regeneration applications.
- dECM (Decellularized Extracellular Matrix) Scaffolds Decellularized allograft/autograft tissues processed using scCO2 technology for implantation, including bone, skin, and pericard scaffolds that support tissue regeneration.
- Closed-Herd Xenograft Platform Proprietary xenograft processing platform enabling applications across surgical disciplines and development of xenotherapeutic organs for human transplantation.
- Antibiotic-Coated Implant Technologies Infection control technologies for medical implants that promise to improve patient outcomes in surgery through antibiotic coating.
- Investigational Medicinal Products (IMPs) GMP-licensed development and production of clinical batches of Investigational Medicinal Products for clinical studies, supported by a Quality Management System based on GMP regulations.
- scCO2 Processing Technology Supercritical CO2 processing service for gentle extraction, purification, impregnation, and terminal sterilization of sensitive biological materials from human and animal origins; used for tissue processing and decellularization.
- Freeze Drying Services Lyophilization technology for preserving biomedical products into dry forms allowing long-term storage while maintaining structure and appearance; multiple freeze dryers available in cleanroom and R&D environments.
- Aseptic Handling Services Aseptic production in ISO- and GMP-compliant cleanrooms (Class A/B/C, ISO 5-7) for sterilization-sensitive products, validated through media fills and requalification processes.
Quantifiable outcome
- scCO2 processing preserves native Extra Cellular Matrix (ECM) composition and growth factors, resulting in excellent biocompatibility and tissue integration upon implantation
- +3 more outcomes
Companies that use HCM Medical
Customer profileSegments4 records
Ideal customer profiles3 records
HCM Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
HCM Medical partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- LifeNet HealthcoreIn August 2025, LifeNet Health acquired HCM Medical in a strategic move to accelerate global access to life-restoring regenerative technologies. HCM Medical brings to LifeNet Health a closed-herd xenograft platform, antibiotic-coated implant technologies, and next-generation sterilization methods. HCM Medical was subsequently rebranded as LifeNet Health Advanced Xeno-Therapeutics (LifeNet Health AXT). Following the acquisition, HCM Medical operates as a Public Benefit Corporation aligned with LifeNet Health's mission-driven focus on patient impact and global health equity.
- RegMed XBminorRegMed XB brings together multiple health foundations, top scientists, entrepreneurs, and governments to cooperatively tackle ambitious challenges in regenerative medicine. HCM Medical joined RegMed XB to share expertise and facilities, provide material and personnel, and serve as a valorization instrument. The partnership focuses on musculoskeletal disease (e.g., osteoarthritis), cardiovascular disease, and organ regeneration.
- Radboud Universiteit (Radboud University)minorHCM Medical collaborates with Radboud Universiteit on research including decellularization of aortas and tracheas. The university provides scientific expertise and access to equipment; students conduct internships at HCM Medical, and HCM Medical provides courses and guest lectures. The collaboration has demonstrated that all cells can be removed from tissues with new cells able to regrow at the same rate as surrounding tissue.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
HCM Medical competitors and assessment
Company assessmentDirect peers
- AGC Biologics: CDMO specializing in mammalian cell culture, microbial fermentation, and aseptic fill-finish of biologics and gene therapies. Comparable as a mid-sized biologics CDMO with clinical and commercial manufacturing capability.
- RTI Surgical: Specializes in tissue-based implants and allograft/xenograft processing for orthopedic, sports medicine, and dental surgical applications. Highly comparable as a tissue-processing CMO with surgical implant focus.
- AlloSource: Non-profit manufacturer of cellular and tissue-based allografts for orthopedic, spine, and wound care applications. Comparable as an accredited tissue processor supplying biologic implants to medical device companies.
- MTF Biologics: Non-profit tissue bank and processor of allograft and xenograft biologics for orthopedic, wound care, and sports medicine. Comparable as a tissue establishment with regulatory accreditations and surgical graft portfolio.
Broad incumbents
- Integra LifeSciences: Medical device company with regenerative tissue technologies (dural repair, dermal matrices, wound care) and contract manufacturing capabilities. Comparable as a downstream user and competitor in collagen and regenerative biomaterials.
- Charles River Laboratories: Provides contract development and manufacturing services for biologics, cell and gene therapies, and preclinical research. Comparable as a broad CDMO serving early-stage biopharma with GMP manufacturing.
- Catalent: Major CDMO offering biologics development, aseptic fill-finish, and clinical supply services. Comparable as a broad incumbent in biologics contract manufacturing and clinical trial material production.
- Lonza Group: Global leader in biologics contract manufacturing with extensive aseptic fill-finish, cell and gene therapy, and microbial fermentation capabilities. Comparable as a large-scale biologics CDMO serving pharmaceutical and biotech customers across multiple modalities.
- WuXi Advanced Therapies Unit: Contract development and manufacturing arm providing cell therapy, gene therapy, and biologics services including aseptic processing. Comparable as a broad incumbent CDMO serving clinical and commercial-stage biopharma globally.
Emerging players
- Fidia Farmaceutici: Specializes in hyaluronic acid-based and regenerative medicine products for orthopedics, wound care, and ophthalmology. Comparable as a regenerative medicine specialty manufacturer with collagen-adjacent biomaterial capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
HCM Medical social profiles
Digital presenceHCM Medical compliance and trust
Trust signalCompliance6 records
HCM Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
HCM Medical leadership team
Management profileNumber of profiles
Profiles2 records
HCM Medical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HCM Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HCM Medical
What does HCM Medical do?
HCM Medical (now LifeNet Health Advanced Xeno-Therapeutics) is a Contract Manufacturing Organization (CMO) that produces biological and biomaterial-based medical products for medical device and pharmaceutical companies. It transforms human and animal tissues into ISO/GMP-compliant medical implants—including collagen products, decellularized extracellular matrix (dECM) scaffolds, xenografts, and Investigational Medicinal Products (IMPs)—using proprietary supercritical CO2 (scCO2) processing, freeze drying, and aseptic handling in ISO Class 5-7 cleanrooms.
Is HCM Medical a public or private company?
HCM Medical is a private company. It is classified as corporate owned and is currently acquired.
When was HCM Medical founded?
HCM Medical was founded in 2014. It employs 11 to 50 people.
Where is HCM Medical based?
HCM Medical is headquartered in Nijmegen, Netherlands, in the Europe region.
How does HCM Medical make money?
One revenue line is on record: contract Manufacturing Organization (CMO) Services.
Who are HCM Medical's main competitors?
Direct peers on record are AGC Biologics, RTI Surgical, AlloSource and MTF Biologics. Broad incumbents are Integra LifeSciences, Charles River Laboratories, Catalent, Lonza Group and WuXi Advanced Therapies Unit. Fidia Farmaceutici is listed as an emerging player.
Does HCM Medical have an API?
No public API is recorded for HCM Medical.
What industry is HCM Medical in?
HCM Medical's product category is Contract Biologics Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325414 and its SIC code is 2836.